TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 33450291

Group type: EXPERIMENTAL
Intervention: Cocaine and cannabis co-use
Number of subjects: 82

Group type: COMPARATOR
Intervention: Cocaine only
Number of subjects: 82

Group type: COMPARATOR
Intervention: Drug negative urine
Number of subjects: 82
Study: 35614405

Group type: EXPERIMENTAL
Intervention: Hysteroscopic management
Number of subjects: 315

Group type: EXPERIMENTAL
Intervention: Ultrasound-guided evacuation
Number of subjects: 315

Group type: COMPARATOR
Intervention: Blind surgical evacuation
Number of subjects: 315
Study: 33609960

Group type: EXPERIMENTAL
Intervention: DOMS-inducing exercise protocol
Number of subjects: 32

Group type: COMPARATOR
Intervention: Control group (no DOMS-inducing exercise protocol)
Number of subjects: 32
Study: 33040573

Group type: EXPERIMENTAL
Intervention: Reflective testing (add-on test results with interpretative comments)
Number of subjects: 270

Group type: COMPARATOR
Intervention: Standard laboratory test results only (control group)
Number of subjects: 270
Study: 32593046

Group type: EXPERIMENTAL
Intervention: 5-plant extract BNO 1012 in addition to standard symptomatic therapy
Number of subjects: 292

Group type: COMPARATOR
Intervention: Standard therapy only
Number of subjects: 292
Study: 33301004

Group type: EXPERIMENTAL
Intervention: Whey protein
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Collagen peptides
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Resistance exercise
Number of subjects: 0
Study: 32400350

Group type: EXPERIMENTAL
Intervention: Operational research approaches and methodologies used by SCORE.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Large cluster-randomized trials conducted by SCORE.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Engagement with stakeholders and sectors in endemic countries.
Number of subjects: 0
Study: 32768592

Group type: EXPERIMENTAL
Intervention: Basiliximab induction with low dose steroids and MMF, delayed introduction of CNI (n=42)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard triple immunosuppression (steroid, tacrolimus, and mycophenolate mofetil) (n=47)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Basiliximab induction
Number of subjects: 89

Group type: COMPARATOR
Intervention: Standard triple immunosuppression
Number of subjects: 89
Study: 35499569

Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TRX518 in combination with gemcitabine (Part C)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TRX518 in combination with pembrolizumab (Part D)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TRX518 in combination with nivolumab (Part E)
Number of subjects: 109

Group type: EXPERIMENTAL
Intervention: TRX518 monotherapy + anti-PD1 combination
Number of subjects: 109
Study: 32829400

Group type: EXPERIMENTAL
Intervention: BCG vaccination at birth
Number of subjects: 2044848

Group type: COMPARATOR
Intervention: No BCG vaccination at birth (control group)
Number of subjects: 2044848
Study: 32809025

Group type: EXPERIMENTAL
Intervention: Rotigotine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 33822027

Group type: EXPERIMENTAL
Intervention: Heavy force (H, 500 g)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Light force (L, 300 g)
Number of subjects: 40
Study: 33553097

Group type: EXPERIMENTAL
Intervention: Campylobacter colonization
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Environmental Enteric Dysfunction (EED)
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Stunting
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Current breastfeeding and ASF consumption
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Improved drinking water supply
Number of subjects: 102

Group type: EXPERIMENTAL
Intervention: Risk factors for stunting
Number of subjects: 102
Study: 35866201

Group type: EXPERIMENTAL
Intervention: Postdischarge SAM relapse
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Postdischarge hospitalisation
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Discharge during the lean season
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Larger household size
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Older child age
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Higher child MUAC at discharge
Number of subjects: 1490

Group type: EXPERIMENTAL
Intervention: Maternal literacy
Number of subjects: 1490
Study: 33548262

Group type: EXPERIMENTAL
Intervention: Ferrous sulfate for 4 months with diet advice
Number of subjects: 60

Group type: COMPARATOR
Intervention: Placebo for 4 months with diet advice
Number of subjects: 60
Study: 33942778

Group type: EXPERIMENTAL
Intervention: Spontaneous breathing
Number of subjects: 30

Group type: COMPARATOR
Intervention: Volume-controlled ventilation mode
Number of subjects: 30
Study: 34151973

Group type: EXPERIMENTAL
Intervention: Prenatal MMS
Number of subjects: 8428

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8428

Group type: EXPERIMENTAL
Intervention: Postnatal MMS
Number of subjects: 8428

Group type: COMPARATOR
Intervention: Postnatal Placebo
Number of subjects: 8428
Study: 33156550

Group type: EXPERIMENTAL
Intervention: Upadacitinib 15 mg once daily
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Upadacitinib 30 mg once daily
Number of subjects: 167

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 167
Study: 35226949

Group type: EXPERIMENTAL
Intervention: ReWin(d) supplement
Number of subjects: 34

Group type: COMPARATOR
Intervention: Maltodextrin (placebo)
Number of subjects: 34
Study: 33977377

Group type: EXPERIMENTAL
Intervention: Robotic camera control
Number of subjects: 100

Group type: COMPARATOR
Intervention: Human camera control
Number of subjects: 100
Study: 34792542

Group type: COMPARATOR
Intervention: OTTO approach (6 weeks of no treatment followed by 6 weeks of OTTO)
Number of subjects: 14

Group type: EXPERIMENTAL
Intervention: Orthotic intervention (6 weeks of orthotic intervention followed by 6 weeks of orthosis plus OTTO)
Number of subjects: 14
Study: 32333897

Group type: EXPERIMENTAL
Intervention: Tocilizumab (8 mg/kg every 4 weeks)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Azathioprine (2‐3 mg/kg per day)
Number of subjects: 118
Study: 33686788

Group type: EXPERIMENTAL
Intervention: Time for Dementia programme
Number of subjects: 386

Group type: COMPARATOR
Intervention: Control group (normal curriculum)
Number of subjects: 386
Study: 33049706

Group type: EXPERIMENTAL
Intervention: Isometric contractions
Number of subjects: 0

Group type: COMPARATOR
Intervention: Isotonic contractions
Number of subjects: 0
Study: 35872131

Group type: EXPERIMENTAL
Intervention: Minimally invasive discectomy
Number of subjects: 222
Study: 33875277

Group type: EXPERIMENTAL
Intervention: Dissonance Induction (DI)
Number of subjects: 1517

Group type: EXPERIMENTAL
Intervention: Assessment Reactivity (AR)
Number of subjects: 1517

Group type: COMPARATOR
Intervention: Control
Number of subjects: 1517
Study: 32696273

Group type: EXPERIMENTAL
Intervention: Beta-distribution based approach
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: CUB (combined uniform and binomial)
Number of subjects: 0
Study: 35879059

Group type: EXPERIMENTAL
Intervention: Goodmorning S Granule®
Number of subjects: 50

Group type: COMPARATOR
Intervention: Bisacodyl
Number of subjects: 50
Study: 34960007

Group type: EXPERIMENTAL
Intervention: Serum plasmalogen dm16:0
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Saturated odd-chain FA 15.0 (pentadecanoic acid)
Number of subjects: 522

Group type: EXPERIMENTAL
Intervention: Omega-3 very long-chain FAs
Number of subjects: 522

Group type: COMPARATOR
Intervention: High serum triglycerides
Number of subjects: 522
Study: 32736776

Group type: COMPARATOR
Intervention: Lymphoma patients
Number of subjects: 449

Group type: COMPARATOR
Intervention: Metastatic solid organ disease patients
Number of subjects: 449
Study: 33946137

Group type: EXPERIMENTAL
Intervention: 3 mL hydro-alcoholic extract of Morus nigra leaves, three times a day
Number of subjects: 100

Group type: COMPARATOR
Intervention: Placebo in water, three times a day
Number of subjects: 100
Study: 34281811

Group type: EXPERIMENTAL
Intervention: Researching Eating, Activity, and Cognitive Health (REACH) Study food frequency questionnaire (FFQ)
Number of subjects: 294
Study: 33246911

Group type: EXPERIMENTAL
Intervention: Azithromycin (AZM), taken thrice-weekly for 18 months
Number of subjects: 221

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 221
Study: 32966830

Group type: EXPERIMENTAL
Intervention: Atezolizumab plus chemotherapy
Number of subjects: 333

Group type: COMPARATOR
Intervention: Placebo plus chemotherapy
Number of subjects: 333
Study: 36121652

Group type: EXPERIMENTAL
Intervention: Weekly 1.7‐mg semaglutide subcutaneous injections for 3 to 6 months
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Weekly 2.4‐mg semaglutide subcutaneous injections for 3 to 6 months
Number of subjects: 408

Group type: EXPERIMENTAL
Intervention: Weekly semaglutide treatment
Number of subjects: 408
Study: 33711671

Group type: EXPERIMENTAL
Intervention: Bevacizumab plus FOLFIRI (5 mg/kg every 2 weeks)
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: Cetuximab plus FOLFIRI (400 mg/m2 then 250 mg/m2 weekly)
Number of subjects: 240

Group type: COMPARATOR
Intervention: Bevacizumab plus FOLFIRI
Number of subjects: 240

Group type: COMPARATOR
Intervention: Cetuximab plus FOLFIRI
Number of subjects: 240

Group type: EXPERIMENTAL
Intervention: BRAF/PIK3CA-mutated tumours
Number of subjects: 240
Study: 33012870

Group type: EXPERIMENTAL
Intervention: Escitalopram 20 mg/day
Number of subjects: 1357

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1357
Study: 35224682

Group type: EXPERIMENTAL
Intervention: Treadmill training (20 min, two sessions per week for 8 weeks)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Routine physical therapy after BoNT‐A injection
Number of subjects: 30
Study: 33482878

Group type: EXPERIMENTAL
Intervention: Acupoint herbal plaster (AHP)
Number of subjects: 166

Group type: COMPARATOR
Intervention: Acupoint placebo plaster (APP)
Number of subjects: 166
Study: 35730342

Group type: EXPERIMENTAL
Intervention: Topical calcipotriol/urea 20% (Group D)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional triamcinolone acetonide (Group C)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional methotrexate (Group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Intralesional 5-fluorouracil (Group A)
Number of subjects: 60
Study: 33002792

Group type: EXPERIMENTAL
Intervention: Internet-based remote rehabilitation project after discharge
Number of subjects: 61

Group type: COMPARATOR
Intervention: Regular telephone follow-up after discharge
Number of subjects: 61
Study: 33289528

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group)
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group (no scratch)
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) after 12 months
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) biochemical pregnancy loss
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group biochemical pregnancy loss
Number of subjects: 933

Group type: EXPERIMENTAL
Intervention: Endometrial scratching (scratch group) miscarriage rate
Number of subjects: 933

Group type: COMPARATOR
Intervention: Control group miscarriage rate
Number of subjects: 933
Study: 33038157

Group type: EXPERIMENTAL
Intervention: Cold riboflavin (4°C)
Number of subjects: 98

Group type: COMPARATOR
Intervention: Control group (riboflavin at room temperature)
Number of subjects: 98
Study: 616497225

Group type: EXPERIMENTAL
Intervention: Bevacizumab targeting therapy
Number of subjects: 92

Group type: COMPARATOR
Intervention: Chemotherapy regimen with oxaliplatin, calcium folinate and 5-fluorouracil (Control)
Number of subjects: 92
Study: 34783447

Group type: EXPERIMENTAL
Intervention: Yellow Yeast Rice (YYR) supplementation
Number of subjects: 0
Study: 33795720

Group type: EXPERIMENTAL
Intervention: Screening arm (SA)
Number of subjects: 80458

Group type: COMPARATOR
Intervention: Control arm (CA)
Number of subjects: 80458
Study: 32349765

Group type: EXPERIMENTAL
Intervention: Artemisinin-based combination therapy (ACT)
Number of subjects: 105

Group type: COMPARATOR
Intervention: Negative control (pooled sera from malaria naïve participants)
Number of subjects: 105
Study: 34028298

Group type: EXPERIMENTAL
Intervention: FIR plus bandage
Number of subjects: 74

Group type: COMPARATOR
Intervention: Standard of care with bandage treatment
Number of subjects: 74
Study: 33025679

Group type: EXPERIMENTAL
Intervention: High sitters
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Low sleepers
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: High sleepers
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: Balanced activity
Number of subjects: 172

Group type: COMPARATOR
Intervention: Younger age
Number of subjects: 172

Group type: COMPARATOR
Intervention: Weaker occupational sitting habit
Number of subjects: 172

Group type: COMPARATOR
Intervention: Stronger walking outside habit
Number of subjects: 172
Study: 35648242

Group type: EXPERIMENTAL
Intervention: Febuxostat
Number of subjects: 1067

Group type: COMPARATOR
Intervention: Non-febuxostat
Number of subjects: 1067

Group type: EXPERIMENTAL
Intervention: Febuxostat (40 mg)
Number of subjects: 1067
Study: 33592205

Group type: EXPERIMENTAL
Intervention: Early peanut consumption
Number of subjects: 341

Group type: COMPARATOR
Intervention: Avoiding peanut
Number of subjects: 341
Study: 34656771

Group type: EXPERIMENTAL
Intervention: Third-trimester ultrasound with measurement of lower uterine segment thickness (LUST) and estimation of fetal weight (EFW)
Number of subjects: 2705

Group type: COMPARATOR
Intervention: No third-trimester ultrasound with measurement of lower uterine segment thickness (LUST) and estimation of fetal weight (EFW)
Number of subjects: 2705
Study: 34301661

Group type: EXPERIMENTAL
Intervention: Removal of prescription charges for 12 months
Number of subjects: 2000

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 2000
Study: 32237005

Group type: EXPERIMENTAL
Intervention: Behavioral economics-based telehealth intervention (up to $50 per month for daily adherence, $2 deduction for missed doses)
Number of subjects: 130

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 130

Group type: EXPERIMENTAL
Intervention: Behavioral economics-based telehealth intervention
Number of subjects: 130
Study: 33448327

Group type: EXPERIMENTAL
Intervention: Ridge regression screening procedure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Traditional one-biomarker-at-a-time screening procedure
Number of subjects: 0
Study: 34077644

Group type: EXPERIMENTAL
Intervention: Nonadjuvanted NmCV‐5
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Alum‐adjuvanted NmCV‐5
Number of subjects: 376

Group type: COMPARATOR
Intervention: MenACWY‐D
Number of subjects: 376
Study: 35229554

Group type: EXPERIMENTAL
Intervention: Remote ischemic conditioning (RIC) during PCI
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 30
Study: 34842524

Group type: EXPERIMENTAL
Intervention: Enhanced standard care plus social recovery therapy
Number of subjects: 270

Group type: COMPARATOR
Intervention: Enhanced standard care alone
Number of subjects: 270
Study: 33549776

Group type: EXPERIMENTAL
Intervention: PECS II block
Number of subjects: 0

Group type: COMPARATOR
Intervention: Non-block
Number of subjects: 0
Study: 32000559

Group type: EXPERIMENTAL
Intervention: Individualized follow-up care with ePROs
Number of subjects: 134

Group type: COMPARATOR
Intervention: Standard follow-up care
Number of subjects: 134
Study: 33232739

Group type: EXPERIMENTAL
Intervention: Drifting ambient temperature (17–25°C with a morning ramp of 2.58°C/h and afternoon ramp of ‐2.58°C/h)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Fixed ambient temperature (21°C)
Number of subjects: 16
Study: 32844495

Group type: EXPERIMENTAL
Intervention: Logarithmic scale for COVID-19 related deaths
Number of subjects: 0

Group type: COMPARATOR
Intervention: Linear scale for COVID-19 related deaths
Number of subjects: 0
Study: 36097940

Group type: EXPERIMENTAL
Intervention: 1SiO2‐1ZrO2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 1SiO2‐2ZrO2
Number of subjects: 140

Group type: EXPERIMENTAL
Intervention: 2SiO2‐1ZrO2
Number of subjects: 140

Group type: COMPARATOR
Intervention: AS
Number of subjects: 140

Group type: COMPARATOR
Intervention: 1SiO2‐4ZrO2
Number of subjects: 140

Group type: COMPARATOR
Intervention: SB
Number of subjects: 140
Study: 32676735

Group type: EXPERIMENTAL
Intervention: Structured reports
Number of subjects: 179

Group type: COMPARATOR
Intervention: Freeform reports
Number of subjects: 179
Study: 32755254

Group type: EXPERIMENTAL
Intervention: Enalapril 10 mg and folic acid 0.8 mg
Number of subjects: 14978

Group type: COMPARATOR
Intervention: Enalapril 10 mg alone
Number of subjects: 14978
Study: 33951261

Group type: EXPERIMENTAL
Intervention: c-Met expression in colorectal cancer tissue
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: ROC analysis of c-Met expression
Number of subjects: 280

Group type: EXPERIMENTAL
Intervention: c-Met expression score of ≥14.50
Number of subjects: 280
Study: 32651322

Group type: EXPERIMENTAL
Intervention: Propofol anesthesia
Number of subjects: 209

Group type: COMPARATOR
Intervention: Sevoflurane anesthesia
Number of subjects: 209
Study: 35153152

Group type: EXPERIMENTAL
Intervention: Two sterile water injections
Number of subjects: 238

Group type: COMPARATOR
Intervention: Four sterile water injections
Number of subjects: 238
Study: 34702280

Group type: EXPERIMENTAL
Intervention: Bouldering-Psychotherapy (BPT)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Cognitive Behavioral Therapy (CBT)
Number of subjects: 0
Study: 32213470

Group type: EXPERIMENTAL
Intervention: internet‐based behavioral activation (iBA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: active control using a brief internet‐based mindfulness intervention (iMBI)
Number of subjects: 104

Group type: COMPARATOR
Intervention: care as usual (CAU)
Number of subjects: 104
Study: 35578051

Group type: EXPERIMENTAL
Intervention: Laparoscopic inguinal hernia repair
Number of subjects: 102

Group type: COMPARATOR
Intervention: Robotic inguinal hernia repair
Number of subjects: 102
Study: 33740276

Group type: EXPERIMENTAL
Intervention: Colloidal bismuth subcitrate (CBS, 125 mg/tab)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: CBS plus high-dose proton-pump inhibitor (PPI), esomeprazole 40 mg q.i.d. for 3 days
Number of subjects: 27

Group type: COMPARATOR
Intervention: No treatment (control)
Number of subjects: 27
Study: 34887572

Group type: EXPERIMENTAL
Intervention: mRNA-1944 at doses of 0.1, 0.3, and 0.6 mg/kg, administered via intravenous infusion
Number of subjects: 38

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 38
Study: 32677891

Group type: EXPERIMENTAL
Intervention: Early oral refeeding (EOR)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual oral refeeding (UOR)
Number of subjects: 0
Study: 36180840

Group type: EXPERIMENTAL
Intervention: Functional Communication Training (FCT)
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Booster parent training session via telehealth
Number of subjects: 48

Group type: COMPARATOR
Intervention: Treatment as usual
Number of subjects: 48
Study: 34052414

Group type: EXPERIMENTAL
Intervention: Warming eye masks generating moist heat at 40 °C for 10 min once daily for 2 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Non-warming eye masks
Number of subjects: 86
Study: 32534647

Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg daily
Number of subjects: 861

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 861
Study: 33663581

Group type: EXPERIMENTAL
Intervention: Higher systolic blood pressure (10-mmHg increase)
Number of subjects: 329237

Group type: EXPERIMENTAL
Intervention: High genetic susceptibility for atrial fibrillation
Number of subjects: 329237

Group type: EXPERIMENTAL
Intervention: Angiotensin-converting enzyme inhibitors, beta-blockers, calcium channel blockers
Number of subjects: 329237
Study: 32152335

Group type: EXPERIMENTAL
Intervention: Melinjo seed extract (MSE) 300 mg/day
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Melinjo seed extract (MSE) 500 or 1000 mg/kg/day
Number of subjects: 42

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 42
Study: 36219518

Group type: EXPERIMENTAL
Intervention: Microneedling followed by PRP (Group A, left side)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Microneedling alone (Group A, right side)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Microneedling followed by PRP (Group B, left side)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Intradermal injection of PRP (Group B, right side)
Number of subjects: 30
Study: 33544361

Group type: EXPERIMENTAL
Intervention: OCD patients
Number of subjects: 328

Group type: COMPARATOR
Intervention: Control groups (anxiety-depressive disorders and general population)
Number of subjects: 328

Group type: EXPERIMENTAL
Intervention: Overall sample
Number of subjects: 328
Study: 32492302

Group type: EXPERIMENTAL
Intervention: Rituximab-chemotherapy
Number of subjects: 328

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 328
Study: 35526432

Group type: EXPERIMENTAL
Intervention: digital CBT-I
Number of subjects: 1721

Group type: COMPARATOR
Intervention: Patient Education
Number of subjects: 1721
Study: 34008833

Group type: EXPERIMENTAL
Intervention: Non-contact CPR training using smart technology (n=31)
Number of subjects: 64

Group type: COMPARATOR
Intervention: General CPR training (n=33)
Number of subjects: 64
Study: 32984080

Group type: EXPERIMENTAL
Intervention: Probiotic group (S. dentisani 7746)
Number of subjects: 59

Group type: COMPARATOR
Intervention: Placebo group
Number of subjects: 59
Study: 36701005

Group type: EXPERIMENTAL
Intervention: Resistance training (2 times weekly, 4 lower body exercises, 3 sets of 6–10 repetitions at 70–85% of 1 repetition maximum)
Number of subjects: 41

Group type: COMPARATOR
Intervention: Control group (passive control)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Resistance training
Number of subjects: 41
Study: 33320315

Group type: EXPERIMENTAL
Intervention: iGel
Number of subjects: 63

Group type: COMPARATOR
Intervention: Cricothyrotomy
Number of subjects: 63
Study: 33566173

Group type: EXPERIMENTAL
Intervention: Standard physiotherapy plus involuntary reflexive pelvic floor muscle training
Number of subjects: 96

Group type: COMPARATOR
Intervention: Standard physiotherapy
Number of subjects: 96
Study: 33441145

Group type: EXPERIMENTAL
Intervention: Early standardized acupuncture
Number of subjects: 67

Group type: COMPARATOR
Intervention: Late standardized acupuncture
Number of subjects: 67